Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rima Rachid

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|September 30, 2018
Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by OmalizumabChristina S K Yee, Sultan Albuhairi, Elizabeth Noh, et al.
The Journal of Allergy and Clinical Immunology|June 24, 2015
TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell developmentNeil Romberg, Manmeet Virdee, Nicolas Chamberlain, et al.
The Journal of Allergy and Clinical Immunology|July 22, 2014
Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivityOliver T Burton, Stephanie L Logsdon, Joseph S Zhou, et al.
Cell Reports. Medicine|November 10, 2021
High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapyGenghao Chen, Ellen L Shrock, Mamie Z Li, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 8, 2018
Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodiesAmanda J Stranks, Samantha C Minnicozzi, Samuel J Miller, et al.
Allergy|January 20, 2026
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut AllergyPhilippe Bégin, Motohiro Ebisawa, Antonella Muraro, et al.
The Journal of Clinical Investigation|September 21, 2013
CVID-associated TACI mutations affect autoreactive B cell selection and activationNeil Romberg, Nicolas Chamberlain, David Saadoun, et al.
The Journal of Allergy and Clinical Immunology|November 24, 2024
The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & ImmunologyAikaterini Anagnostou, J Andrew Bird, Sharon Chinthrajah, et al.
Nature Medicine|June 26, 2019
Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergyAzza Abdel-Gadir, Emmanuel Stephen-Victor, Georg K Gerber, et al.
Nature Medicine|August 18, 2019
Author Correction: Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergyAzza Abdel-Gadir, Emmanuel Stephen-Victor, Georg K Gerber, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Allergy and Clinical Immunology. in Practice|September 30, 2018
Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by OmalizumabChristina S K Yee, Sultan Albuhairi, Elizabeth Noh, et al.
The Journal of Allergy and Clinical Immunology|June 24, 2015
TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell developmentNeil Romberg, Manmeet Virdee, Nicolas Chamberlain, et al.
The Journal of Allergy and Clinical Immunology|July 22, 2014
Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivityOliver T Burton, Stephanie L Logsdon, Joseph S Zhou, et al.
Cell Reports. Medicine|November 10, 2021
High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapyGenghao Chen, Ellen L Shrock, Mamie Z Li, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 8, 2018
Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodiesAmanda J Stranks, Samantha C Minnicozzi, Samuel J Miller, et al.
Allergy|January 20, 2026
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut AllergyPhilippe Bégin, Motohiro Ebisawa, Antonella Muraro, et al.
The Journal of Clinical Investigation|September 21, 2013
CVID-associated TACI mutations affect autoreactive B cell selection and activationNeil Romberg, Nicolas Chamberlain, David Saadoun, et al.
The Journal of Allergy and Clinical Immunology|November 24, 2024
The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & ImmunologyAikaterini Anagnostou, J Andrew Bird, Sharon Chinthrajah, et al.
Nature Medicine|June 26, 2019
Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergyAzza Abdel-Gadir, Emmanuel Stephen-Victor, Georg K Gerber, et al.
Nature Medicine|August 18, 2019
Author Correction: Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergyAzza Abdel-Gadir, Emmanuel Stephen-Victor, Georg K Gerber, et al.
Pageof 6